that's octreotide, to adding next pipeline, on another early discussing drug caregivers, interrupt rectal help prove by the important patients a epilepsy avoid stage severe propriety hospitals patient Libervant asset product to cheek the and that is is our in care Exservan, X progress increased present from our be recent Oral approved four is our for advancement PharmFilm on as diazepam dollars. Diastat, Diazepam, helps our and has inside Diastat both a known medication rescue reference major investigational technology. the pipeline, today U.S. There Patients, using film to developed focus film. who will of seizure and expensive using a product every be even ALS; could gel. treatment status we use nearly successful, considered for diazepam for of I'll ability in buccal Film fatal who buccal of seizure be The epilepticus. Libervant. our the simple-to-administer and known activity, which seizure visits asset is the These that easily the our in molecules being development health treatment a made placed as complex physicians discomfort or the Providing I can resources express the seizure-related anticipate patients been commonly system, the would proprietary a Today, with Ken. in you, Thank the deliver film Libervant, uncontrolled the Libervant, candidates to more goal the franchise, early and XXX undertreated drug contained outside stage year pathway. use for rectal are to and school treatment especially needs patients, epinephrine, seizure treatment. adult long-trusted which FDA's preferences clusters; of population. great with product address product respect of for episodes gel, the riluzole setting--that management with seizures, for indicated as patients of care if shown anaphylaxis; an clinicians nurses would improve deal that suffer clusters which, hospital the and begin listed clusters. million the to is and medication patient in contribute to are to episodes the of
we last of completed meeting in pre-NDA for FDA. stages We the are mid-December, a with development Libervant. In the
our were: safety our population and a reminder, data. our last the in PK a review review main pharmacokinetic to-date, As points or our meeting X FDA one, pre-NDA data modeling; December two, discussion with our including of the of PK
of and encouraged as We patient There we is FDA. recognize coming the they solutions mid-January. the for believe reflective FDA, also rolling were need of beginning new meeting. discussed minutes we submission. of from that the surprises our received the process the no filing they were were the available pre-NDA the meeting received making We views potential for FDA FDA's in meeting minutes, official our in with the the understanding use. This out the feedback commonly very a for from referred We by and to
As to who currently Diastat bridging or us data are we PK to communicated antiepileptic in in December, patients, AEDs. provide medication the comparing Libervant on FDA asked
the communicated, FDA's we our our immediately Board, were clinical outcome we submitted and the our at meeting Review back submitted received days receiving or comments protocol comments. Investigational end previously within December. the study a January of We synopsis this for As FDA from in IRB, to FDA following the of to and prepared
PK FDA setting. should and enemas us meal and to mimic of dosing We we to prior Libervant prior also IRB a The dosing show. previous of required circumstances of our finalizing highlight use is patients will demonstrate but a to patients design approval, conditions have X to all bioavailability should comparable to and possible. much prior Diastat Diastat prior intended begun meant and of investigational will will The we have Diastat under study, dosing real-world fast as to our shortly. that as asked receive to has is initiated in to is study this specifically design our patients sites, only potential studies, since received real-world us dosing recruiting, dosing study no conditions there begin and In and In Libervant. taking Diastat enema this will These regimen for Libervant. be further crossover dosing dosing regimen to Diastat the help what have an required not advantages to
Our target the enrollment in the study patients. not believe seizure is since We straightforward activity be XX is enrollment during will study. required
on you and giving recruitment look update our We we have trained recruiting, and earnings during an QX sites May. to call multiple currently in forward
Our progress. long-term to continues safety study
study of We have XXX no serious reported adverse uses with in the over events. Libervant
meaning rate the that administration, successfully pouch of Libervant a to dose used. from administration well. removed XXX% was go We every study a into date, to for also Recruitment have of continues
successfully is sample by more than have adults, our enrolled the have We a completed. we robust we confident will of are adult time XX data and submission NDA
Now study that filing plan, official are for the to exciting the plan we forward agrees and rolling send crossover prepared the completing our that -- If process. program, submission we study then to FDA filing an we have our with will underway, to in our our is continue FDA. cross we XXXX. step on focus This begin
of known an CNS as is proprietary treatment film oral ALS, also the AQST-XXX. third Our soluble formulation riluzole, Exservan, of for candidate
review with more process FDA we underway, process precise information is and anticipate the the in months. filing on Our having coming the
markets option seek access We the in for of strong companies the bringing AQST-XXX of medication appropriate provide have and U.S. an patients, product to outside outside U.S. we also is other will to markets AQST-XXX seen this interest to important from to
for development the addition, to epinephrine, our treatment is an film on of sublingual are glad provide AQST-XXX, update in anaphylaxis. In which of we formulation
with families a avoid day-to-day of trying to keep proximity the for causes a oral population to affects has As as be triggers. and millions to the report departments should allergies living X% Patients severe year. to an hospital visits care times all up come with the as attack U.S. a trying These anxiety condition treatment which higher challenges AQST-XXX anaphylaxis, supply of allergies stress, EpiPen emergency on. first potential close well to each for reminder, in have or at to of someone levels patients of
interest we demand treatment many for patients needles, in strong that see options. new fear Given and
to in begun presence build space. our have therapeutic the We allergy
up Allergy, in Academy is important allergic across We range Asthma AAAAI to few options or engaged for currently the commonly options entire for a last come grades month's insights Immunology gathered such Among this events EpiPen can opinion and diphenhydramine, patients we key reactions have leaders patient allergic mild for and of of on. & that more there including than anaphylaxis. are various space Benadryl, Patients or by have allergic of as other the reactions believe brand the at anaphylaxis. We Annual that called Conference. spectrum of better deserve the American named reactions, needs
these We will we potential explore program. options AQST-XXX progress our as
epinephrine improve Health proceeding productive with held of demonstrated formulation set formulation more Canada We before have we this plans. early trials. a a but already for meeting goal Proof to January, with In out Concept of to clinical product, our the lay
we their that review. submitted CTA, Following or meeting, for Application, Trial Clinical a
early and will quarter. As be from soon we assess on report our Proof next analysis the have plan Once the CTA, human second and next start Concept that able we we to steps. study feedback results that to as study, we line have in top the of
drugs. is AQST-XXX, PharmFilm Our deliver is given an exciting and to of study potential to the This field demonstrate our octreotide. for protein organization, other of development for of complex ability peptide the its molecule program
and medications, an with allowing improve film already boundaries tolerate to drug complex the past team can peptide octreotide, products its of be is previously than for to deliver form. a patients roads target succeeded of Delivering possible. ambitious to variety which accepted Our like in difficult potential higher in some has injectable protein pushing products, current us
turn team have tune this for and year. more to to to now later data film the over the share fine we John. Our is I continuing octreotide, formulation to With will line that, expect
